The foundation Stichting Eigen Regie, (kvk) 70567573 was established on januari 8 th 2018.                               It's core activities were wound management.This came to a hold in 2020 during Covid-19.It's expertise led to the development of new antibiotics.                       As a start-up,BeneluxBio does its own in-house research and has licensed compounds from Liberpharma.                                                                           Liberpharma became in 2022 the trading name of the Stichting Eigen Regie.
With a commitment to innovation and patient care, we aim to develop new medicines that address infectious diseases and myoblastoma,multiple myeloma ( via molecular glues)                                         Many compounds were designed and developed under a program of the NCI
Director is mr. J.H.A. Cornelesen
We are gratefull to our former director                              mr. R.G. Dassen (Itteren,Netherlands)for his relentless commitment to the Stichting Eigen Regie